drugset / Trial / NCT04885712
A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
RandomizedParallel-groupTriple-blindTreatment
Summary
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or Pioglitazone 30mg Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin
Timeline
- Start
- 2021-05-28
- Primary completion
- 2022-09-19
- Completion
- 2023-03-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pioglitazone | Small molecule | 15 mg | — |
| Subject | Pioglitazone | Small molecule | 30 mg | — |
| Background | Dapagliflozin | Small molecule | 10 mg | — |
| Background | Metformin | Small molecule | 1000 mg | — |